Skip to main content

Golimumab Effective in non-radiographic Axial Spondyloarthritis

The GO-AHEAD study was designed to assess the long-term efficacy and safety of golimumab (GLM) in non-radiographic axial spondyloarthritis (nr-axSpA).  After the 16-week, placebo [PBO]-controlled double-blind phase, 189/198 (95.5%) entered the long-term extension (OLE) for 36 weeks wherein GLM patients continued on GLM (GLM/GLM) and PBO treated patients were then given GLM (PBO/GLM).

Between weeks 16–52 in OLE in both GLM/GLM and PBO/GLM groups improved their efficacy outcomes from weeks 16 to 52:

  • ASAS 20: GLM/GLM group went from 71.1% to 83.9%  and PBO/GLM improved from 40.0% to 75.0%
  • ASAS40: GLM/GLM group went from 56.7% to 76.3%  and PBO/GLM improved from 23.0% to 59.4%,

Adverse events were lower in the GLM/GLM vs PBO/GLM groups (41.9% and 54.2%).

GLM was well tolerated and provided substantial long-term benefits to patients with nr-axSpA. 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject